Skip navigation
Please use this identifier to cite or link to this item: https://mnclhd.intersearch.com.au/mnclhdjspui/handle/123456789/646
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBrooks, P. M.-
dc.contributor.authorMcCredie, M.-
dc.contributor.authorProwse, M.-
dc.contributor.authorPodgorski, M.-
dc.contributor.authorForrest, M.-
dc.contributor.authorMunro, I.-
dc.contributor.authorBoutagy, J.-
dc.contributor.authorPei-Ling, L.-
dc.date.accessioned2025-06-05T02:03:11Z-
dc.date.available2025-06-05T02:03:11Z-
dc.date.issued1986-
dc.identifier.citationPharmatherapeutica. 1986;4(10):665-72en
dc.identifier.urihttps://mnclhd.intersearch.com.au/mnclhdjspui/handle/123456789/646-
dc.description.abstractThe pharmacokinetics of isoxicam, a new non-steroidal anti-inflammatory drug, were studied in 20 osteoarthritis patients with varying degrees of renal insufficiency. A wide variation in pharmacokinetic parameters was seen between individuals but there was no suggestion that renal function influenced pharmacokinetics. Steady state plasma isoxicam concentrations varied from 20 micrograms/ml to 130 micrograms/ml, while the plasma half-life varied from 23 hours to 58 hours. Despite a reduction in urinary prostaglandin E2 excretion, isoxicam administration did not alter renal function over a 4-week period.en
dc.language.isoenen
dc.subjectisolxicamen
dc.subjectDinoprostoneen
dc.subjectAnti-Inflammatory Agents, Non-Steroidalen
dc.subjectRenal Insufficiencyen
dc.subjectOsteoarthritisen
dc.titlePharmacokinetics and effects of isoxicam on renal function in patients with renal insufficiencyen
dc.typeArticleen
dc.contributor.mnclhdauthorProwse, Michael V.-
dc.description.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/3602018/en
Appears in Collections:Medicine

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Google Media

Google ScholarTM

Who's citing